• Tarun Prabhala, Shelby Sabourin, Marisa DiMarzio, Michael Gillogly, Julia Prusik, and Julie G Pilitsis.
• Department of Neurosurgery, Albany Medical College, Albany, New York, USA.
• Neuromodulation. 2019 Feb 1; 22 (2): 215-218.

ObjectiveSpinal cord stimulation (SCS) has been shown to be effective in treating chronic pain in patients with varying etiologies. However, the impact of pharmacological treatment on augmenting response to SCS has not been previously studied.MethodsWe enrolled 108 patients who had undergone SCS surgery and documented their pain preoperatively and at 12 months postoperatively using the Numeric Rating Scale (NRS), McGill Pain Questionnaire (MPQ), Beck Depression Inventory (BDI), Oswestry Disability Index (ODI), Pain Catastrophizing Scale (PCS), and Global Impression of Change (GIC). Pain outcomes were compared between patients receiving SCS alone and in addition to duloxetine.ResultsAt 1-year follow-up, patients receiving duloxetine and SCS (n = 41) had better pain relief in the affective component of MPQ (p < 0.05) than those receiving SCS alone (n = 71). Patients on duloxetine with SCS also were significantly more willing to receive SCS again (p < 0.01). This willingness appeared to be duloxetine dose dependent (p < 0.05). Patients receiving pregabalin or gabapentin with SCS did not have significantly more pain relief than patients receiving SCS alone.ConclusionThis study shows the combination therapy to be an effective strategy to provide more holistic pain relief and further improve the quality of life of SCS patients.© 2018 International Neuromodulation Society.

26 keywords...

hide…